002390SZSE

Announcement on the Provision of Asset Impairment Provisions by Guizhou Xinbang Pharmaceutical Co., Ltd. for 2025

✨ AI Summary

Guizhou Xinbang Pharmaceutical Co., Ltd. announces its provision for asset impairment losses for 2025. The company recognized RMB 907.68 million in credit impairment losses and RMB 216.75 million in other asset impairment losses. These provisions are expected to reduce the total profit for 2025 by RMB 1,124.43 million. The provisions comply with accounting standards and are based on prudent principles.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002390 Securities Abbreviation: Xinbang Pharmaceutical Announcement No.: 2026-012

Guizhou Xinbang Pharmaceutical Co., Ltd. Announcement on the Provision of Asset Impairment Provisions for 2025

The Company and all members of the Board of Directors guarantee the content of the information disclosed is true, accurate, and complete, and there is no false record, misleading statement, or major omission.

Guizhou Xinbang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") deliberated and passed the "Proposal on the Provision of Asset Impairment Provisions for 2025" at the tenth meeting of the ninth Board of Directors held on April 17, 2026. The matter is hereby announced as follows:

I. Situation of the Company's Provision for Asset Impairment Losses This Time

(I) Credit Impairment Loss Situation

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.